Annexin Pharmaceuticals AB (publ) (STO:ANNX)
Sweden flag Sweden · Delayed Price · Currency is SEK
13.70
-0.15 (-1.08%)
May 21, 2026, 12:14 PM CET

STO:ANNX Cash Flow Statement

Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-39.44-36.89-50.25-44.05-40.73-52.14
Depreciation & Amortization
0.190.190.190.190.190.19
Other Operating Activities
-0-000-5.19
Change in Accounts Payable
0.040.01-1.371-0.180.61
Change in Other Net Operating Assets
0.2-0.241.2-0.54-0.451.13
Operating Cash Flow
-39-36.93-50.23-43.4-41.17-45.02
Capital Expenditures
-0.13-0.13----
Investment in Securities
---0.1-0.26-
Investing Cash Flow
-0.13-0.13-0.1-0.26-
Long-Term Debt Issued
--510-20
Net Debt Issued (Repaid)
--510-20
Issuance of Common Stock
11.3149.9740.0626.523.1166.66
Other Financing Activities
-0.34-1.860.1-2.9-0.05-10.29
Financing Cash Flow
10.9748.1145.1533.6123.0676.37
Miscellaneous Cash Flow Adjustments
---0-0--
Net Cash Flow
-28.1611.06-5.08-9.7-18.3731.35
Free Cash Flow
-39.13-37.05-50.23-43.4-41.17-45.02
Free Cash Flow Per Share
--5.60-11.11-25.97-28.14-54.88
Cash Interest Paid
--0.050--
Levered Free Cash Flow
-24-22.86-31.51-26.87-26.05-28.92
Unlevered Free Cash Flow
-24-22.86-31.48-26.87-26.05-27.76
Change in Working Capital
0.24-0.23-0.170.46-0.631.74
Source: S&P Global Market Intelligence. Standard template. Financial Sources.